MARKET

RGEN

RGEN

Repligen Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

305.01
-1.89
-0.62%
Opening 14:36 09/20 EDT
OPEN
301.33
PREV CLOSE
306.90
HIGH
310.94
LOW
297.91
VOLUME
351.89K
TURNOVER
--
52 WEEK HIGH
310.94
52 WEEK LOW
138.00
MARKET CAP
16.77B
P/E (TTM)
171.17
1D
5D
1M
3M
1Y
5Y
Brown Capital Management Small Company Fund Buys 10x Genomics Inc, Smartsheet Inc, Alarm. ...
GuruFocus News · 1d ago
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study
Zacks.com · 3d ago
Keybanc Maintains Overweight on Repligen, Raises Price Target to $335
Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $255 to $335.
Benzinga · 3d ago
KeyBanc Raises Price Target on Repligen to $335 From $255, Keeps Overweight Rating
MT Newswires · 3d ago
Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal
Benzinga · 4d ago
Repligen To Acquire Avitide For $150M
Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised o...
Benzinga · 4d ago
BRIEF-Repligen Reports Agreement To Acquire Avitide
reuters.com · 4d ago
Repligen to Acquire Chromatography Developer Avitide in $150 Million Cash-And-Stock Deal
MT Newswires · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RGEN. Analyze the recent business situations of Repligen Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RGEN stock price target is 267.88 with a high estimate of 335.00 and a low estimate of 232.00.
EPS
Institutional Holdings
Institutions: 548
Institutional Holdings: 52.74M
% Owned: 95.92%
Shares Outstanding: 54.98M
TypeInstitutionsShares
Increased
131
3.70M
New
50
348.53K
Decreased
157
2.89M
Sold Out
79
423.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.16%
Healthcare Equipment & Supplies
-2.04%
Key Executives
Chairman/Independent Director
Karen Dawes
President/Chief Executive Officer/Director
Anthony Hunt
Chief Financial Officer
Jon Snodgres
Senior Vice President
James Bylund
Senior Vice President
Christine Gebski
Senior Vice President
Ralf Kuriyel
Independent Director
Nicolas Barthelemy
Independent Director
Carrie Manner
Independent Director
Rohin Mhatre
Independent Director
Glenn Muir
Independent Director
Thomas Ryan
No Data
About RGEN
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.

Webull offers kinds of Repligen Corporation stock information, including NASDAQ:RGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGEN stock methods without spending real money on the virtual paper trading platform.